NCT03500263View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

March 13, 2019

Study Completion Date

March 13, 2019

Conditions

Cystic Fibrosis

Interventions

DRUG

PTI-808

Active

DRUG

Placebo

DRUG

PTI-801

Active

DRUG

PTI-428

Active

DRUG

Placebo

Trial Locations (4)

BT9 6AD

Celerion, Belfast

EH4 2XU

Western General Hospital, Edinburgh

G514TF

Queen Elizabeth University Hospital, Glasgow

Unknown

Medicines Evaluation Unit, Manchester

All Listed Sponsors

lead

Proteostasis Therapeutics, Inc.

INDUSTRY

NCT03500263 - Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis | Biotech Hunter | Biotech Hunter